Ionis Pharmaceuticals (IONS) Interest & Investment Income (2009 - 2026)

Ionis Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at $25.5 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 3.31% year-over-year to $25.5 million in Q1 2026; TTM through Mar 2026 was $98.6 million, a 6.47% decrease from a year earlier, with the FY2025 full-year figure at $97.8 million, down 8.65% from the prior year.
• Interest & Investment Income advanced to $25.5 million in Q1 2026 per IONS's latest filing, from $24.7 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $28.9 million in Q4 2024 and bottomed at $2.0 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $24.7 million (2025), against an average of $20.2 million.
• Across the five-year window, Interest & Investment Income slumped 57.08% in 2022 and surged 834.62% in 2023, its largest moves.
• Year by year, Interest & Investment Income stood at $11.9 million in 2022, then soared by 116.14% to $25.7 million in 2023, then advanced by 12.55% to $28.9 million in 2024, then fell by 14.46% to $24.7 million in 2025, then increased by 3.05% to $25.5 million in 2026.
• Per Business Quant, the three latest IONS Interest & Investment Income figures stand at $25.5 million (Q1 2026), $24.7 million (Q4 2025), and $23.7 million (Q3 2025).